Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020)

BridgeBio Pharma's Non-Current Deferred Tax Liability history spans 1 years, with the latest figure at $1.1 million for Q4 2020.

  • For Q4 2020, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the TTM value through Dec 2020 reached $1.1 million, changed N/A, while the annual FY2020 figure was $1.1 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2020 was $1.1 million at BridgeBio Pharma.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.1 million in Q4 2020 and bottomed at $1.1 million in Q4 2020.